Epizyme (EPZM) Raised to Hold at BidaskClub

Epizyme (NASDAQ:EPZM) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Thursday.

Other research analysts have also recently issued reports about the stock. Cann reiterated a “buy” rating and issued a $27.00 target price on shares of Epizyme in a report on Thursday, August 2nd. Cowen reiterated a “buy” rating on shares of Epizyme in a report on Monday, September 24th. Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a report on Friday, July 6th. ValuEngine upgraded shares of Epizyme from a “sell” rating to a “hold” rating in a report on Thursday, July 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Epizyme in a report on Wednesday, June 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company’s stock. Epizyme currently has a consensus rating of “Buy” and an average price target of $21.00.

Shares of EPZM opened at $9.34 on Thursday. Epizyme has a 12-month low of $8.61 and a 12-month high of $21.40. The company has a market capitalization of $736.73 million, a PE ratio of -4.28 and a beta of 1.65.

Epizyme (NASDAQ:EPZM) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.11. The firm had revenue of $12.00 million during the quarter, compared to analyst estimates of $0.54 million. During the same quarter in the previous year, the business earned ($0.48) earnings per share. The business’s quarterly revenue was up 20.0% compared to the same quarter last year. Research analysts expect that Epizyme will post -2.14 earnings per share for the current fiscal year.

In related news, Director David M. Mott purchased 416,667 shares of the firm’s stock in a transaction that occurred on Friday, October 5th. The stock was acquired at an average cost of $9.00 per share, for a total transaction of $3,750,003.00. Following the completion of the acquisition, the director now owns 12,088 shares in the company, valued at approximately $108,792. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 21.50% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. Northern Trust Corp boosted its holdings in shares of Epizyme by 12.1% during the second quarter. Northern Trust Corp now owns 651,179 shares of the biopharmaceutical company’s stock worth $8,823,000 after purchasing an additional 70,281 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Epizyme by 2.7% during the second quarter. Bank of New York Mellon Corp now owns 225,764 shares of the biopharmaceutical company’s stock worth $3,058,000 after purchasing an additional 6,012 shares during the period. Redmile Group LLC boosted its holdings in shares of Epizyme by 0.5% during the second quarter. Redmile Group LLC now owns 2,021,389 shares of the biopharmaceutical company’s stock worth $27,390,000 after purchasing an additional 9,400 shares during the period. Opaleye Management Inc. boosted its holdings in shares of Epizyme by 292.9% during the second quarter. Opaleye Management Inc. now owns 275,000 shares of the biopharmaceutical company’s stock worth $3,726,000 after purchasing an additional 205,000 shares during the period. Finally, Bank of America Corp DE boosted its holdings in shares of Epizyme by 19.8% during the second quarter. Bank of America Corp DE now owns 65,569 shares of the biopharmaceutical company’s stock worth $889,000 after purchasing an additional 10,855 shares during the period. Institutional investors and hedge funds own 85.06% of the company’s stock.

About Epizyme

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

Featured Article: Diversification

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply